Banning DTC Rx ads will not lower drug prices, says US Budget Office
This article was originally published in SRA
Executive Summary
Banning direct-to-consumer advertising for new prescription medicines in the US is unlikely to help reduce consumer spending on drugs and could result in drug makers changing their marketing strategy by spending more on promoting their products to physicians, the Congressional Budget Office has stated in an issue brief1.
You may also be interested in...
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.